Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer

Prostate Cancer and Prostatic Diseases volume 19, pages 57–62 (2016)Cite this article

Subjects

Abstract

Background:

We prospectively examined influence of androgen deprivation therapy (ADT) on lipid and glucose metabolisms in Japanese patients with prostate cancer.

Methods:

Patients with prostate cancer who were hormone-naive and scheduled to receive long-term ADT were recruited between 2011 and 2013. Body weight, abdominal circumference and blood testing associated with lipid and glucose metabolism were recorded every 3 months during 1 year of ADT. Computed tomography (CT) was performed to measure areas of subcutaneous and visceral fat before and after 1 year of ADT. ADT was limited to a luteinizing hormone-releasing hormone (LHRH) agonist with or without bicalutamide.

Results:

Of 218 patients registered, data were available from 177 patients who completed 1 year of ADT. Of these, CT was performed before and after 1 year of ADT in 88 patients. Median age was 75 years (range, 49–85 years). Median PSA before ADT was 16.7 ng ml−1 (range, 0.3–3316). Clinical stage was B (54.2%), C (23.2%) and D (20.9%). Mean increases in body weight and abdominal circumference after 1 year of ADT were 2.9 and 3.0%, respectively. Mean increases in total, low-density lipoprotein and high-density lipoprotein cholesterol and triglycerides were 10.6, 14.3, 7.8 and 16.2%, respectively. Mean increases in fasting blood sugar and hemoglobin A1c (HbA1c) were 3.9 and 2.7%, respectively. Lipid alterations were noted in patients without comorbidities, whereas changes in HbA1c were noted in patients with diabetes mellitus at baseline. These lipid and glucose alterations were prominent in the early ADT period. Both visceral and subcutaneous fat, as measured by CT, increased by >20%. The increase in subcutaneous fat was significantly greater than that in visceral fat (P=0.028).

Conclusions:

One year of ADT significantly changed lipid and glucose metabolism in Japanese patients with prostate cancer. Patient characteristics or comorbidities at baseline may be associated with ADT-induced metabolic changes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Saylor PJ, Smith MR . Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2013; 189: S34–S44.

    Article  CAS  PubMed  Google Scholar 

  2. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M . Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2014; 68: 386–396.

    Article  PubMed  Google Scholar 

  3. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K . The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 657–660.

    Article  CAS  PubMed  Google Scholar 

  4. Torimoto K, Samma S, Kagebayashi Y, Chihara Y, Tanaka N, Hirayama A et al. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol 2011; 41: 577–581.

    Article  PubMed  Google Scholar 

  5. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361–2367.

    Article  PubMed  Google Scholar 

  6. Nowicki M, Bryc W, Kokot F . Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Invest 2001; 24: 31–36.

    Article  CAS  PubMed  Google Scholar 

  7. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546–2553.

    Article  CAS  PubMed  Google Scholar 

  8. Smith MR . Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742–745.

    PubMed  Google Scholar 

  9. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599–603.

    Article  CAS  PubMed  Google Scholar 

  10. Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA et al. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology 2014; 83: 1316–1321.

    Article  PubMed  Google Scholar 

  11. Timilshina N, Breunis H, Alibhai SM . Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer. J Urol 2012; 188: 2183–2188.

    Article  CAS  PubMed  Google Scholar 

  12. Eri LM, Urdal P, Bechensteen AG . Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995; 154: 100–104.

    Article  CAS  PubMed  Google Scholar 

  13. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377–383.

    Article  CAS  Google Scholar 

  14. Smith MR, Lee H, Nathan DM . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305–1308.

    Article  CAS  PubMed  Google Scholar 

  15. Cheung KK, Luk AO, So WY, Ma RC, Kong AP, Chow FC et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: a review of current evidence. J Diabetes Investig 2015; 6: 112–123.

    Article  CAS  PubMed  Google Scholar 

  16. Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR . Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014; 65: 816–824.

    Article  CAS  PubMed  Google Scholar 

  17. Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA et al. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int 2013; 90: 41–44.

    Article  CAS  PubMed  Google Scholar 

  18. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261–4267.

    Article  CAS  PubMed  Google Scholar 

  19. Lee H, McGovern K, Finkelstein JS, Smith MR . Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 1633–1637.

    Article  CAS  PubMed  Google Scholar 

  20. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK et al. Major lipids, apolipoproteins, and risk of vascular disease. 2009 JAMA 302: 1993–2000.

    Article  Google Scholar 

  21. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A . Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308.

    Article  CAS  PubMed  Google Scholar 

  22. O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M . Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2015; 33: 1243–1251.

    Article  CAS  PubMed  Google Scholar 

  23. De Maddalena C, Vodo S, Petroni A, Aloisi AM . Impact of testosterone on body fat composition. J Cell Physiol 2012; 227: 3744–3748.

    Article  CAS  PubMed  Google Scholar 

  24. Matsushita Y, Nakagawa T, Yamamoto S, Takahashi Y, Yokoyama T, Noda M et al. Associations of visceral and subcutaneous fat areas with the prevalence of metabolic risk factor clustering in 6,292 Japanese individuals: the Hitachi Health Study. Diabetes Care 2010; 33: 2117–2119.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kuk JL, Church TS, Blair SN, Ross R . Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome? Diabetes Care 2006; 29: 679–684.

    Article  PubMed  Google Scholar 

  26. Eguchi M, Tsuchihashi K, Saitoh S, Odawara Y, Hirano T, Nakata T et al. Visceral obesity in Japanese patients with metabolic syndrome: reappraisal of diagnostic criteria by CT scan. Hypertens Res 2007; 30: 315–323.

    Article  PubMed  Google Scholar 

  27. Hoang KC, Le TV, Wong ND . The metabolic syndrome in East Asians. J Cardiometab Syndr 2007; 2: 276–282.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The following doctors conducted data collection and completed case report forms: Haruo Nakagawa, Akihiro Ito, Shigeyuki Yamada (Tohoku University), Shingo Hatakeyama, Takahiro Yoneyama (Hirosaki University), Takamitsu Inoue, Kazuyuki Numakura, Norihiko Tsuchiya (Akita University), Tatsuo Tochigi, Sadafumi Kawamura (Miyagi Cancer Center), Junichiro Koyama (Shirakawa Kosei General Hospital), Seiji Ueno (Osaki City Hospital), Fumihiko Soma (Hachinohe City Hospital), Shinnosuke Kato (Ogachi Chuo Hospital), Yoshikatsu Tanahashi (Tanahashi Yoshikatsu Clinic) and Senji Hoshi (Yamagata Prefectural Central Hospital).

Author information

Authors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai,, Japan

    K Mitsuzuka & Y Arai

  2. Department of Urology, Shirakawa Kosei General Hospital, Shirakawa,, Japan

    A Kyan & T Sato

  3. Department of Urology, Kesen-numa City Hospital, Kesen-numa,, Japan

    K Orikasa

  4. Department of Urology, Ryukyu University, Nishihara,, Japan

    M Miyazato

  5. Department of Urology, Sendai City Hospital, Sendai,, Japan

    H Aoki

  6. Department of Urology, Miyagi Cancer Center, Natori,, Japan

    N Kakoi

  7. Department of Urology, Akita University School of Medicine, Akita,, Japan

    S Narita & T Habuchi

  8. Department of Urology, Hirosaki University School of Medicine, Hirosaki,, Japan

    T Koie & C Ohyama

  9. Department of Urology, Tohoku Rosai Hospital, Sendai,, Japan

    T Namima

  10. Department of Urology, Sendai Jin Hinyokika Clinic, Sendai,, Japan

    S Toyoda

  11. Department of Urology, Sendai Yanagyu Clinic, Sendai,, Japan

    Y Fukushi

Authors
  1. K Mitsuzuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Kyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Orikasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Miyazato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Kakoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Koie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Namima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Toyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y Fukushi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Habuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Y Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Tohoku Evidence-Based Medicine Study Group

The Michinoku Urological Cancer Study Group

Corresponding author

Correspondence to K Mitsuzuka.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mitsuzuka, K., Kyan, A., Sato, T. et al. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis 19, 57–62 (2016). https://doi.org/10.1038/pcan.2015.50

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2015.50

This article is cited by

Search

Advanced search

Quick links